Healthcare Enterprise Group market a product called "Ebiox" which is one of a very few that can kill most bacteria including the MRSA superbug. HCEG has contracts with some NHS hospitals at present, but given the recent and current news and public attention, HCEG should be a good bet for a steady rise as more places seek to cut the number of casualties from this infection. HCEG also market abroad in USA, so the potential market for this unique product is massive indeed.

Well worth a punt IMHO

Check it out for yourself

Morning all. Nice to see we are blue again.

I love blue

Nice 2.5 million delayed trade has just shown up.

There seems to be no shortage of buyers this morning. Would expect to see another tick up soon.

HCEFF is Healthcare Enterprise Group Inc., listed on the Nasdaq Over The Counter (OTC) market.

It was formed in February 2001 as a result of a collaboration between London & Paific Healthcare Development, Inc. (LPHD) and Moore Clayton & Co, Inc. (MCCI).

LPHD is a life sciences private equity and advisory firm founded in November 1998 by its principals, Stuart Bruck and Michael Low.

MCCI is a financial advisory firm specialising in the financial services, media and communications and energy industries and was founded in 1999.

HCEFF was used to takeover Interactivity Group Plc. (a shell company with a UK AIM listing) ... due to the respective sizes of the two companies it was viewed by the LSE as a reverse takeover i.e. after the deal Interactivity Plc. owned the entire issued share capital of HCEFF.

Interactivity Plc. then changed it's name to Healthcare Enterprise Group Plc. (HCEG.)

In a nutshell, HCEFF had obtained a UK (AIM) listing for it's business ... quicker and cheaper than floating the business themselves.

HCEG Plc. is currently the holding company of the HCEGI healthcare development business, which provides strategic advice and associated services primarily to early stage companies operating in the healthcare sector in return for fees which are payable in cash, equity or equity related securities.

I doubt you'll ever see any announcements from HCEFF ... all their stock (shares) are owned by HCEG Plc. so will not be traded on the Nasdaq OTC market.

I've no doubt that retaining a US listing is a good thing ... one day HCEG Plc. may want a US listing and they will be able to do it quickly and cheaply (again) using HCEFF.

Good to see buyers taking advantage of that dip.

Buying is picking up again

Has anyone been contacted by a broker called Edward Tate & Co. The firm is not registered with FSA. Beware!

Alert from FSA concerning this company at:

http://www.fsa.gov.uk/enforcement/edward_tate_24june04.pdf

A nice 2 million buy has just shown up.

AGM scheduled for 11.00am on monday 26/july

Healthcare Enterprise Group PLC
23 July 2004



Healthcare Enterprise Group PLC


Increased shareholding in Ebiox Limited



Healthcare Enterprise Group PLC ('HCEG' or the 'Group'), the healthcare products
and services company, has acquired an approximate further 2% in Ebiox Limited ('
Ebiox') giving HCEG an effective majority holding of 51% of Ebiox, which owns a
range of proprietary cleansing and decontamination products for use in the
healthcare industry.



HCEG will pay 50,000 in cash and 35,000 in HCEG shares to Keith MacGregor, the
vendor, contingent upon the achievement of specific agreed 'milestones'. These
milestones relate to, amongst other things, the further testing of the product.



Furthermore, HCEG has granted four put options to the vendor to require HCEG to
purchase the remaining 49% of the share capital of Ebiox in four tranches
contingent upon the achievement of further agreed milestones. The consideration
payable upon exercise of each put option will be 250,000 to be satisfied in
cash, or by the issuance of HCEG shares, for each of the four tranches.



The vendor has also agreed to grant HCEG a call option to acquire the remaining
share capital of Ebiox so as to give HCEG an effective 100% of the share capital
of Ebiox. The consideration payable upon exercise of the call option will be up
to 1,000,000 to be satisfied in cash, or by the issuance of HCEG shares.



The put and call arrangements are in substitution for the option arrangements
entered into in February 2004 and announced at that time.



In the year end to 31 March 2003, the latest date for which accounts are
available, Ebiox made a loss of 51,161 on turnover of 57,643.



Stuart Bruck, Executive Chairman, Healthcare Enterprise Group PLC, commented:



'Ebiox products are already being used in 50 National Health Service hospitals
in the UK and has achieved a range of important milestones, which makes this an
attractive transaction for HCEG. Moreover, this new deal gives HCEG effective
control over the development of this exciting range of world class products. It
also provides for the outright acquisition of Ebiox once it has produced the
relevant results.'



23 July 2004

Enquiries:

Healthcare Enterprise Group 020 7351 7500
Stuart Bruck, Executive Chairman
Gordon Wood, Group Chief Operating Officer

College Hill 020 7457 2020
Nicholas Nelson
Corinna Dorward



Notes to Editors

Ebiox



Ebiox produces a range of patented cleansing, decontamination and disinfectant
products. The range includes hand hygiene products, hard surface cleaners,
disinfectants and products to clean and decontaminate surgical instruments.



The Ebiox antibacterial handwash and handrub are proven effective against MRSA,
E-coli and other important pathogens and are fully compliant with EU standards.
Uniquely, the products do not use alcohol, which has a drying effect and can be
a skin irritant.



The hard surface cleaners, particularly the TrionicPlus trigger spray and
Azowipe Active wipes are based on a lifting and removing concept, completely
removing biofilms and cleaning to molecular level. The product continues to be
active after use and cleans through oxidation action, not toxification which
means that there is no need to rotate disinfectants because there is no chance
of resistance developing (cf GMP guidelines).



Ebiox also offers a range of products for the effective cleaning of re-usable
instruments. Critically, these products remove all debris prior to the
sterilisation process thereby ensuring complete decontamination. They have
proven to be more effective than natural detergents and enzymatic detergents
currently available.



As well as the current range of products, Ebiox also has products for the
decontamination of dental aspiration lines and a veterinary product range,
EbioxVET.



Healthcare Enterprise Group PLC



HCEG is quoted on the UK AIM stock market with its head office in London and
subsidiary offices in Manchester, Liverpool, Cheshire, Germany and the USA.
HCEG is a business engaged in medical product distribution, occupational health,
first aid and medical consultancy markets. These businesses underpin a range of
innovative medical devices, which will be introduced to the market via HCEG's
own distribution network on an international basis.





This information is provided by RNS
The company news service from the London Stock Exchange

With MRSA in the news and the Government with egg all over its face, HCEG must be a good buy. The NHS just cannot afford to take no action. It must take steps to stop the spread of the MRSA virus. Any firm offering a solution is bound to prosper. Hold tight!

A nice 1 million buy has just gone through.

What is MRSA?
Staphylococcus aureus is a bacterium often found in 20-30% of the noses of normal healthy people and is also commonly found on people's skin. Most strains of this bacterium are sensitive to many antibiotics and infections can be effectively treated. Staphylococcus aureus which are resistant to an antibiotic called methicillin are referred to as methicillin-resistant Staphylococcus aureus or MRSA. Many commonly prescribed antibiotics are not effective against these bacteria. Some MRSA strains occur in epidemics, indicated by an 'E' before MRSA eg EMRSA-16, EMRSA-3 and may be distinguished from others by a number of special laboratory techniques.

How is spread of MRSA prevented?
Scrupulous handwashing by hospital staff before and after contact with patients and before any procedure, is the single most important infection control measure. It is most likely to prevent spread of MRSA from one patient to another, or from patient to member of staff who may subsequently pass the bacterium on to other patients. Patients with MRSA should be physically isolated in a single room with the door remaining closed and the room regularly damp dusted, or they should be nursed in a special ward away from other non-infected patients. The patient's notes should be clearly labelled 'MRSA' so that this type of accommodation is provided if and when they are admitted to hospital at any time in the future. It is important that the clinician looking after the patient in hospital notifies the general practitioner. If this has not already been done, then the patient or their family should mention to their general practitioner that they are carrying MRSA. This information should also be passed to any hospital to which the patient may be admitted in the future to ensure physical separation or isolation immediately on admission and hence reduce the possibility of spread to others. The use of antibiotics such as those applied inside the nose and bathing procedures previously described, will also help to reduce the risk of spread. Finally, when such a patient is discharged from hospital, their room should be comprehensively cleaned and all linen and other clinical waste disposed of in special bags.

A 5.2 million buy has just shown up!

Nice one

Buys v sells, 8.4 million v 4.4 million

USA approval read link for RNShttp://www.uk-wire.com/cgi-bin/articles/200407260700021800B.html

yep, more good news.

NS Number:1800B
Healthcare Enterprise Group PLC
26 July 2004


Healthcare Enterprise Group plc

Ebiox surface cleaning product passes tests required for US Environment
Protection Agency approval

Healthcare Enterprise Group PLC ("HCEG"), the healthcare products and services
company, announces that its Trionic Plus product from the Ebiox family of
products has passed tests required for US Environment Protection Agency (EPA).
EPA approval will allow the product to be offered to US hospitals and related
facilities and for industrial antimicrobial and other cleaning uses in the US.

Trionic Plus is a high power "terminal" disinfectant proven to be effective at
combating MRSA and other pathogens. HCEG believes that the product offers
significant safety advantages over all other commonly used disinfectants and
does not contain alcohol, chlorine or other irritating vapours.

Trionic Plus contains soil lifting agents and biocides, which allow removal of
soils and microbes down to the molecular level. It removes the invisible
surface biofilms, which are believed to provide a rich breeding ground for the
development of resistant bacteria.

For high-risk contaminated areas Trionic Plus provides a fast-kill solution for
bacteria on hygienic surfaces such as floors, walls, tables, beds and public
access areas. Unlike other commonly used surface cleaners, Trionic Plus works
by oxidation rather than toxification. This means that there is no need to
rotate disinfectants because there is no chance of bacterial resistance
developing.

HCEG is considering a range of US marketing and distribution options for Trionic
Plus, together with similar strategies for its surgical instrument cleaner
range, which received EPA approval in March.

Stuart Bruck, Chairman, Healthcare Enterprise Group PLC, commented:

"The US represents over half of the world's healthcare economy, with an annual
expenditure in excess of US$1.7 trillion and is a market with which we are
familiar. The sheer size of the market means entry into the US represents an
exciting opportunity for the Ebiox product range.

Since the US tends to lead in the adoption of new healthcare technologies, we
are confident that the obvious benefits these products have over existing
alcohol or bleach disinfectants will result in active product investigation and
assessment by US hospitals and other healthcare facilities."

26 July 2004